Xtant Medical announced the U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft substitute designed and cleared for spinal fusion. The Matriform Si Strip is resorbable, osteoconductive and has a cancellous bone-like structure. The product is prepared from Beta-tricalcium phosphate (β-TCP) and porcine collagen, with an intended use of filling and bridging degenerative or traumatic bone defects.
Kevin Brandt, Xtant Medical’s Chief Commercial Officer, said, “We are excited to launch Matriform Si in the U.S., which expands our biologics portfolio offering and increases our footprint in the U.S. orthopedic Bone Graft Substitute market. This innovative synthetic is an ultraporous, interconnected structure that is designed to enhance new bone formation and mechanical stability while preventing premature dissolution for spinal fusion procedures.”
Xtant Medical announced the U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft substitute designed and cleared for spinal fusion. The Matriform Si Strip is resorbable, osteoconductive and has a cancellous bone-like structure. The product is prepared from Beta-tricalcium phosphate (β-TCP) and porcine collagen,...
Xtant Medical announced the U.S. commercial launch of the Matriform Si, a silicated synthetic bone graft substitute designed and cleared for spinal fusion. The Matriform Si Strip is resorbable, osteoconductive and has a cancellous bone-like structure. The product is prepared from Beta-tricalcium phosphate (β-TCP) and porcine collagen, with an intended use of filling and bridging degenerative or traumatic bone defects.
Kevin Brandt, Xtant Medical’s Chief Commercial Officer, said, “We are excited to launch Matriform Si in the U.S., which expands our biologics portfolio offering and increases our footprint in the U.S. orthopedic Bone Graft Substitute market. This innovative synthetic is an ultraporous, interconnected structure that is designed to enhance new bone formation and mechanical stability while preventing premature dissolution for spinal fusion procedures.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
